216 related articles for article (PubMed ID: 12512835)
1. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.
Tobinai K
Int J Hematol; 2002 Dec; 76(5):411-9. PubMed ID: 12512835
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.
Igarashi T; Kobayashi Y; Ogura M; Kinoshita T; Ohtsu T; Sasaki Y; Morishima Y; Murate T; Kasai M; Uike N; Taniwaki M; Kano Y; Ohnishi K; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
Ann Oncol; 2002 Jun; 13(6):928-43. PubMed ID: 12123339
[TBL] [Abstract][Full Text] [Related]
6. 4. Antibody therapy for malignant lymphoma.
Tobinai K
Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
[TBL] [Abstract][Full Text] [Related]
7. Re-treatment of relapsed indolent B-cell lymphoma with rituximab.
Igarashi T; Ohtsu T; Fujii H; Sasaki Y; Morishima Y; Ogura M; Kagami Y; Kinoshita T; Kasai M; Kiyama Y; Kobayashi Y; Tobinai K;
Int J Hematol; 2001 Feb; 73(2):213-21. PubMed ID: 11372734
[TBL] [Abstract][Full Text] [Related]
8. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
Tobinai K
Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
[TBL] [Abstract][Full Text] [Related]
10. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
11. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
12. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
13. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
14. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
[TBL] [Abstract][Full Text] [Related]
17. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
Lin TS; Blum KA; Fischer DB; Mitchell SM; Ruppert AS; Porcu P; Kraut EH; Baiocchi RA; Moran ME; Johnson AJ; Schaaf LJ; Grever MR; Byrd JC
J Clin Oncol; 2010 Jan; 28(3):418-23. PubMed ID: 20008633
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
19. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
Hainsworth JD
Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
[TBL] [Abstract][Full Text] [Related]
20. Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study.
Bremer K
Anticancer Drugs; 2003 Nov; 14(10):809-15. PubMed ID: 14597875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
